JP7317039B2 - 線維症を処置するための化合物および組成物 - Google Patents

線維症を処置するための化合物および組成物 Download PDF

Info

Publication number
JP7317039B2
JP7317039B2 JP2020552690A JP2020552690A JP7317039B2 JP 7317039 B2 JP7317039 B2 JP 7317039B2 JP 2020552690 A JP2020552690 A JP 2020552690A JP 2020552690 A JP2020552690 A JP 2020552690A JP 7317039 B2 JP7317039 B2 JP 7317039B2
Authority
JP
Japan
Prior art keywords
group
mkp
compound
thio
pharmaceutical composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2020552690A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021506975A5 (https=
JP2021506975A (ja
Inventor
アントン ベネット
ジョナサン エルマン
ハヤ ジャマリ
カレン エス． アンダーソン
エリアス ロリス
デントン ホイヤー
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Yale University
Original Assignee
Yale University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Yale University filed Critical Yale University
Publication of JP2021506975A publication Critical patent/JP2021506975A/ja
Publication of JP2021506975A5 publication Critical patent/JP2021506975A5/ja
Priority to JP2023116635A priority Critical patent/JP7676477B2/ja
Application granted granted Critical
Publication of JP7317039B2 publication Critical patent/JP7317039B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/78—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C07D491/052—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being six-membered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/34—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase
    • C12Q1/42—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase involving phosphatase
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/914—Hydrolases (3)
    • G01N2333/916—Hydrolases (3) acting on ester bonds (3.1), e.g. phosphatases (3.1.3), phospholipases C or phospholipases D (3.1.4)

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Pulmonology (AREA)
  • Cardiology (AREA)
  • Analytical Chemistry (AREA)
  • Biophysics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Biotechnology (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Neurology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • General Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Peptides Or Proteins (AREA)
JP2020552690A 2017-12-18 2018-12-18 線維症を処置するための化合物および組成物 Active JP7317039B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2023116635A JP7676477B2 (ja) 2017-12-18 2023-07-18 線維症を処置するための化合物および組成物

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762607110P 2017-12-18 2017-12-18
US62/607,110 2017-12-18
PCT/US2018/066191 WO2019126141A1 (en) 2017-12-18 2018-12-18 Compounds and compositions for treating fibrosis

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2023116635A Division JP7676477B2 (ja) 2017-12-18 2023-07-18 線維症を処置するための化合物および組成物

Publications (3)

Publication Number Publication Date
JP2021506975A JP2021506975A (ja) 2021-02-22
JP2021506975A5 JP2021506975A5 (https=) 2022-01-06
JP7317039B2 true JP7317039B2 (ja) 2023-07-28

Family

ID=66993802

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2020552690A Active JP7317039B2 (ja) 2017-12-18 2018-12-18 線維症を処置するための化合物および組成物
JP2023116635A Active JP7676477B2 (ja) 2017-12-18 2023-07-18 線維症を処置するための化合物および組成物

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2023116635A Active JP7676477B2 (ja) 2017-12-18 2023-07-18 線維症を処置するための化合物および組成物

Country Status (9)

Country Link
US (3) US11504373B2 (https=)
EP (1) EP3732179B1 (https=)
JP (2) JP7317039B2 (https=)
KR (1) KR20200100726A (https=)
CN (2) CN116687934A (https=)
AU (3) AU2018388549B2 (https=)
CA (1) CA3085770A1 (https=)
MX (2) MX2020006398A (https=)
WO (1) WO2019126141A1 (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2023145544A (ja) * 2017-12-18 2023-10-11 イエール ユニバーシティ 線維症を処置するための化合物および組成物

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12570670B2 (en) * 2019-01-30 2026-03-10 Yale University Compounds, compositions, and methods for treating fibrosis

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2003530112A (ja) 2000-04-10 2003-10-14 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフトング 二重特異性ホスファターゼｄｕｓｐ−１０の同定
WO2014176488A1 (en) 2013-04-26 2014-10-30 Indiana University Research & Technology Corporation Hydroxyindole carboxylic acid based inhibitors for oncogenic src homology-2 domain containing protein tyrosine phosphatase-2 (shp2)

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE60125783T2 (de) * 2000-08-11 2007-10-18 Evotec Ag Verfahren zum nachweis von acetylase oder deacetylase-aktivität in einem immunoassay
US20030162230A1 (en) * 2000-09-27 2003-08-28 Reagan Kevin J. Method for quantifying phosphokinase activity on proteins
JP2007518702A (ja) * 2003-11-25 2007-07-12 ノバルティス アクチエンゲゼルシャフト ソマトスタチン類似体処置の効力についてのバイオマーカー
US8546410B2 (en) 2008-05-05 2013-10-01 Abbvie Inc. Heteroaryl-fused macrocyclic pyrimidine derivatives
EP2351571A4 (en) * 2008-10-09 2012-08-01 Lsip Llc PROTEINPHOSPHATASEHEMMER
AU2018388549B2 (en) * 2017-12-18 2023-06-01 Yale University Compounds and compositions for treating fibrosis

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2003530112A (ja) 2000-04-10 2003-10-14 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフトング 二重特異性ホスファターゼｄｕｓｐ−１０の同定
WO2014176488A1 (en) 2013-04-26 2014-10-30 Indiana University Research & Technology Corporation Hydroxyindole carboxylic acid based inhibitors for oncogenic src homology-2 domain containing protein tyrosine phosphatase-2 (shp2)

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Basic & Clinical Pharmacology & Toxicology，2015年，Vol.117，p.96-104

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2023145544A (ja) * 2017-12-18 2023-10-11 イエール ユニバーシティ 線維症を処置するための化合物および組成物
JP7676477B2 (ja) 2017-12-18 2025-05-14 イエール ユニバーシティ 線維症を処置するための化合物および組成物

Also Published As

Publication number Publication date
AU2018388549B2 (en) 2023-06-01
KR20200100726A (ko) 2020-08-26
JP2021506975A (ja) 2021-02-22
JP2023145544A (ja) 2023-10-11
EP3732179B1 (en) 2024-05-01
EP3732179A1 (en) 2020-11-04
EP3732179A4 (en) 2022-01-19
US20240335445A1 (en) 2024-10-10
CN111670188A (zh) 2020-09-15
AU2023204581A1 (en) 2023-10-05
AU2023204581B2 (en) 2025-06-26
CN116687934A (zh) 2023-09-05
US20200390770A1 (en) 2020-12-17
MX2020006398A (es) 2020-09-07
CA3085770A1 (en) 2019-06-27
MX2023009895A (es) 2023-09-04
CN111670188B (zh) 2023-06-23
AU2025234269A1 (en) 2025-10-16
US20230181588A1 (en) 2023-06-15
WO2019126141A1 (en) 2019-06-27
JP7676477B2 (ja) 2025-05-14
US11504373B2 (en) 2022-11-22
AU2018388549A1 (en) 2020-07-02

Similar Documents

Publication Publication Date Title
KR100840727B1 (ko) 아데노신 ａ1, ａ2ａ 및 ａ3 수용체 특이 화합물 및 그의 사용방법
JP7676477B2 (ja) 線維症を処置するための化合物および組成物
PL204628B1 (pl) Pochodna pirolo[2,3d]pirymidyny, jej zastosowanie i sposoby wytwarzania tej pochodnej i preparaty farmaceutyczne
US10738061B2 (en) Inhibitors of RAD52 recombination protein and methods using same
JP2023030014A (ja) チオールイソメラーゼ阻害剤およびその使用
US9469625B2 (en) Organic compounds
CA2813743C (en) Selective proton coupled folate transporter and folate receptor, and garftase and/or other folate metabolizing enzymes inhibitor compounds and methods of using the same
CN109824693B (zh) Brd4抑制剂及其在肿瘤治疗药物中的应用
CN112390782B (zh) 一种特异性增强TRPV4-KCa2.3复合体的空间耦联度的化合物及其用途
CN100496495C (zh) 糖尿病引起的缺血性心脏病的治疗和/或预防药
HK40098110A (zh) 用於治疗纤维化的化合物和组合物
US12570670B2 (en) Compounds, compositions, and methods for treating fibrosis
JP2002526450A (ja) Ｃｈｋ１キナーゼ阻害物質
US20230064189A1 (en) 1h-pyrazolo[3,4-d]pyrimidine compounds useful for the treatment of platinum-resistant cancer
US12552773B2 (en) Compound for specifically enhancing spatial coupling degree of TRPV4-KCa2.3 complex and use thereof
CN104072432B (zh) 含苯基取代三唑希夫碱类结构的化合物、其制备方法和用途
WO2016188481A1 (zh) 苯并吡唑联吡啶类化合物、包含此类化合物的药物组合物及其用途
JP2002338467A (ja) アデニル酸シクラーゼ５型阻害剤
CN104496926B (zh) 一类含二烯四氮唑结构的化合物、其制备方法和用途
CN104496925B (zh) 二烯四氮唑类化合物、其制备方法和用途

Legal Events

Date Code Title Description
RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20210113

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210113

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20211129

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20211129

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20221219

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20230320

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230419

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20230619

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20230718

R150 Certificate of patent or registration of utility model

Ref document number: 7317039

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150